CoChat
Sign Up
Cited by 65

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Structural characterization of human liver heparan sulfate

Vongchan, Preeyanat, Warda, Mohamad, Toyoda, Hidenao, Toida, Toshihiko, Marks, Rory M., Linhardt, Robert J.·2005·Biochimica et Biophysica Acta (BBA) - General Subjects
DOI 10.1016/j.bbagen.2004.09.007
Open this paper in CoChat — free account

Abstract

The isolation, purification and structural characterization of human liver heparan sulfate are described. 1H-NMR spectroscopy demonstrates the purity of this glycosaminoglycan (GAG) and two-dimensional 1H-NMR confirmed that it was heparan sulfate. Enzymatic depolymerization of the isolated heparan sulfate, followed by gradient polyacrylamide gel, confirmed its heparin lyase sensitivity. The concentration of resulting unsaturated disaccharides was determined using reverse phase ion-pairing (RPIP) HPLC with post column derivatization and fluorescence detection. The results of this analysis clearly demonstrate that the isolated GAG was heparan sulfate, not heparin. Human liver heparan sulfate was similar to heparin in that it has a reduced content of unsulfated disaccharide and an elevated average sulfation level. The antithrombin-mediated anti-factor Xa activity of human liver heparan sulfate, however, was much lower than porcine intestinal (pharmaceutical) heparin but was comparable to standard porcine intestinal heparan sulfate. Moreover, human liver heparan sulfate shows higher degree of sulfation than heparan sulfate isolated from porcine liver or from the human hepatoma Hep 2G cell line.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.bbagen.2004.09.007

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 37

  1. Belting, 2003, HS proteoglycan as a plasma membrane, Trends Biochem. Sci., 28, 145, 10.1016/S0968-0004(03)00031-8 · DOI · Paper page
  2. Park, 2000, Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters, J. Biol. Chem., 275, 29923, 10.1074/jbc.R000008200 · DOI
  3. Lander, 1996, The glypican family of heparan sulfate proteoglycans: major, Perspect. Dev. Neurobiol., 3, 347
  4. Filmus, 2001, Glypicans: proteoglycans with a surprise, J. Clin. Invest., 108, 497, 10.1172/JCI200113712 · DOI
  5. Selva, 2001, Role of heparan sulfate proteoglycans in cell signaling and cancer, Adman. Cancer Res., 83, 67, 10.1016/S0065-230X(01)83003-7 · DOI
  6. Iozzo, 2001, HS proteoglycans: heavy hitters in the angiogenesis arena, J. Clin. Invest., 108, 349, 10.1172/JCI200113738 · DOI
  7. Iozzo, 2001, Heparan sulfate proteoglycans: intricate molecules with intriguing functions, J. Clin. Invest., 108, 165, 10.1172/JCI200113560 · DOI
  8. Turnbull, 2001, Heparan sulfate: decoding a dynamic multifunctional cell regulator, Trends Cell Biol., 11, 75, 10.1016/S0962-8924(00)01897-3 · DOI
  9. Bazin, 2002, Inhibition of apolipoprotein E-related neurotoxicity by glycosaminoglycans and their oligosaccharides, Biochemistry, 41, 8203, 10.1021/bi025817e · DOI
  10. Castillo, 1997, Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability, J. Neurohemal., 69, 2452, 10.1046/j.1471-4159.1997.69062452.x · DOI · Paper page
  11. Lin, 2002, Heparin inhibits dengue-2 virus infection of five human liver cell lines, Antivir. Res., 56, 93, 10.1016/S0166-3542(02)00095-5 · DOI
  12. Pradel, 2002, Proteoglycans mediate malaria sporozoite targeting to the liver, Mol. Microbiol., 45, 637, 10.1046/j.1365-2958.2002.03057.x · DOI
  13. Barth, 2003, Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate, J. Biol. Chem., 278, 41003, 10.1074/jbc.M302267200 · DOI
  14. Mc Clean, 1916, The thromboplastic action of cephalin, Am. J. Physiol., 41, 250, 10.1152/ajplegacy.1916.41.2.250 · DOI
  15. Lyon, 1994, Liver heparan sulfate structure, J. Biol. Chem., 269, 11208, 10.1016/S0021-9258(19)78112-5 · DOI · Paper page
  16. Hernáiz, 2002, Purification and characterization of heparan sulfate peptidoglycans from bovine liver, Carbohydr. Polym., 48, 153, 10.1016/S0144-8617(01)00229-6 · DOI
  17. Toida, 1997, Structural differences and the presence of unsubstituted amino groups in heparan sulfates from different tissues and species, Biochem. J., 322, 499, 10.1042/bj3220499 · DOI
  18. Horner, 1986, Rat heparins, Biochem. J., 240, 171, 10.1042/bj2400171 · DOI
  19. Kresse, 1993, Small proteoglycans, Experimenta, 49, 403, 10.1007/BF01923585 · DOI
  20. Rathore, 2001, Direct measurement of the interaction of glycosaminoglycans and a heparin hexasaccharide with malaria circumsporozoite protein, Biochemistry, 40, 11518, 10.1021/bi0105476 · DOI
  21. Chen, 1997, Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate, Nature Med., 3, 866, 10.1038/nm0897-866 · DOI
  22. Wellnitz, 2002, Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines, J. Virol., 76, 1181, 10.1128/JVI.76.3.1181-1193.2002 · DOI
  23. Capila, 2002, Heparin–protein interactions, Angew. Chem., Int. Ed., 41, 390, 10.1002/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-B · DOI · Paper page
  24. Park, 1999, Purification and characterization of heparan sulfate proteoglycans from bovine liver, Biochem. J., 344, 723, 10.1042/0264-6021:3440723 · DOI
  25. Griffin, 1995, Isolation and characterization of heparan sulfate from crude porcine intestinal mucosa peptidoglycan heparin, Carbohydr. Res., 276, 183, 10.1016/0008-6215(95)00166-Q · DOI
  26. Toyoda, 1999, Rapid and sensitive analysis of disaccharide composition in heparin and heparan sulfate by reversed-phase ion-pair chromatography on a 2μm porous silica gel column, J. Chromatogr., A, 830, 197, 10.1016/S0021-9673(98)00854-1 · DOI
  27. Liang, 1997, Glypican and biglycan in the nuclei of neurons and glioma cells: presence of functional nuclear localization signals and dynamic changes in glypican during the cell cycle, J. Cell Biol., 139, 851, 10.1083/jcb.139.4.851 · DOI
  28. Gu, 1993, Comparison of the activity of two chondroitin AC lyases on dermatan sulfate, Carbohydr. Res., 244, 369, 10.1016/0008-6215(83)85014-9 · DOI
  29. Edens, 1992, Gradient polyacrylamide gel electrophoresis for determination of molecular weights of heparin preparations and low-molecular-weight heparin derivatives, J. Pharm. Sci., 81, 823, 10.1002/jps.2600810821 · DOI
  30. Merchant, 1985, Structure of heparin derived tetrasaccharides, Biochem. J., 229, 369, 10.1042/bj2290369 · DOI
  31. Gallagher, 1985, Molecular distinctions between heparan sulfate and heparin. Analysis of sulfation patterns indicates that heparan sulfate and heparin are separate families of N-sulfated polysaccharides, Biochem. J., 230, 665, 10.1042/bj2300665 · DOI
  32. Linhardt, 2004, Role of glycosaminoglycans in cellular communication, Accounts Chem. Res., 37, 431, 10.1021/ar030138x · DOI
  33. WuDunn, 1989, Initial interaction of herpes simplex virus with cells is binding to heparan sulfate, J. Virol., 63, 52, 10.1128/JVI.63.1.52-58.1989 · DOI
  34. Yanagishita, 1998, Cellular catabolism of heparan sulfate proteoglycans, TIGG, 10, 57, 10.4052/tigg.10.57 · DOI
  35. Sung, 1999, Oxidative stress is insignificant in N1S1-transplanted hepatoma despite markedly declined activities of the antioxidant enzymes, Nocl, Reports, 6, 1313
  36. Dong-Yun, 2003, Redox stress regulates cell proliferation and apoptosis of human hepatoma through Akt protein phosphorylation, FEBS Lett., 542, 60, 10.1016/S0014-5793(03)00338-7 · DOI
  37. Nakatsura, 2003, Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor maker, Biochem. Biophys. Res. Commun., 306, 16, 10.1016/S0006-291X(03)00908-2 · DOI

Cited by

Sorted by citations

Metadata

Authors
Vongchan, P., Warda, M., Toyoda, H., Toida, T., Marks, R. M., & Linhardt, R. J.
Venue
Biochimica et Biophysica Acta (BBA) - General Subjects
Publisher
Elsevier BV
Published
2005-01
Volume
1721
Issue
1-3
Pages
1-8
ISSN
0304-4165
DOI
10.1016/j.bbagen.2004.09.007
Cited by
65
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review